Company / Total Assets
Jade Biosciences, Inc. Total Assets History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$80.3M
FY2024
5-year range
$4.7M / $175.4M
FY2020-FY2024
Trend
-37.0%
vs FY2023
Sector context
#210 of 215
Health Care
What the data says
Among 215 Health Care companies, Jade Biosciences, Inc. is in the bottom 2% for total assets. Total Assets has declined for 3 consecutive years, from $175M in FY2021 to $80M in FY2024.
Based on SEC 10-K filings.
$80M in FY2024 with a 3-year CAGR of -22.9%.
Declined from $135M to $80M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -22.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 215This company $80.3M Sector average $7.5B
▼
-98.9% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s total assets has declined for 3 consecutive years.
- 3-year CAGR of -22.9%, indicating a declining trend.
- In FY2024, total assets decreased 37.0% year-over-year.
- Ranks #210 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $80.3M | -37.0% |
| FY2023 | $127.4M | -5.8% |
| FY2022 | $135.3M | -22.8% |
| FY2021 | $175.4M | +3619.3% |
| FY2020 | $4.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026